Recent studies have shown that, in addition to inducing necroptosis in prostate cancer cells, the PLK1 inhibitor BI2536 sensitizes esophageal squamous cell carcinoma cells to cisplatin in vivo and in vitro by inhibiting the DNA damage repair and promoting pyroptosis (257). This evidence concerns the gene PLK1 and prostate cancer.